ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
Status:
RECRUITING
Trial end date:
2026-12-25
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis